JCO:化疗后ALL患儿常发生脊椎骨折

2012-07-10 练晶军 爱唯医学网

       加拿大渥太华大学的Leanne M. Ward博士等人研究发现,因急性淋巴细胞性白血病(ALL)而接受化疗的儿童常发生椎骨骨折。这项研究提前发表在《临床肿瘤学杂志》(J Clin Oncol)6月25日在线版上。         诊断ALL时背痛和脊椎骨密度偏

       加拿大渥太华大学的Leanne M. Ward博士等人研究发现,因急性淋巴细胞性白血病(ALL)而接受化疗的儿童常发生椎骨骨折。这项研究提前发表在《临床肿瘤学杂志》(J Clin Oncol)6月25日在线版上。
 
JCO:化疗后ALL患儿常发生脊椎骨折

       诊断ALL时背痛和脊椎骨密度偏低,分别与12个月内脊椎骨折风险增加独立相关。诊断ALL前后发生椎骨骨折也与今后的骨折风险相关。Ward博士指出:“这一现象在成人骨质疏松症相关文献中被称为‘椎骨骨折级联反应’,而我们首次发现在儿童中也存在这一现象。”

       上述研究结果来自儿科患者类固醇相关性骨质疏松症(STOPP)数据库。在招募的155例ALL患儿中,25例(16%)完成了12个月的数据采集,共发生61次椎骨骨折。52次(85%)骨折发生于既往正常的椎体,其余9次骨折是原有骨折的加重。

       13例患儿在基线时已有新发骨折或再发骨折,12个月随访期间发生的骨折大多数(45/61,74%)来自这些患儿。研究者认为这一亚组患儿可能在骨折方面存在遗传易感性。

       糖皮质激素或甲氨蝶呤用药剂量与新发椎骨骨折无关,但12个月随访期间体重指数增加与新发骨折风险增加有关。

       如何预防或治疗这类骨折仍是悬而未决的问题。“随着患儿骨骼发育,骨折椎体可发生改形。某些诊断时已有骨折的患儿,在接受白血病化疗的情况下仍会发生骨折椎体改形。我们正在分析数据,以确定哪些患儿最可能发生椎体改形和纠正其脊柱畸形,同时也确定哪些患儿不能发生椎体改形。”

       关于双膦酸盐在儿童中的使用,Ward博士认为这要视具体情况而定。“目前儿童使用双膦酸盐的最常见情况是,患儿发生了多处骨折,或者脊椎骨折导致了严重背痛。”

       研究者还将继续对受试患儿随访5年,主要骨健康结局包括多种骨骼脆性参数(椎体骨折的发生率和改形,以及骨密度)。研究者希望根据这些数据明确ALL患儿的骨健康自然史和发病情况。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891009, encodeId=f2c418910095f, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Mar 27 06:09:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328833, encodeId=cdce13288336d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Jul 12 06:09:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630481, encodeId=366f163048157, content=<a href='/topic/show?id=dd238456e9f' target=_blank style='color:#2F92EE;'>#脊椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84567, encryptionId=dd238456e9f, topicName=脊椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80c21536506, createdName=neizongke, createdTime=Thu Jul 12 06:09:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
    2013-03-27 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891009, encodeId=f2c418910095f, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Mar 27 06:09:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328833, encodeId=cdce13288336d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Jul 12 06:09:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630481, encodeId=366f163048157, content=<a href='/topic/show?id=dd238456e9f' target=_blank style='color:#2F92EE;'>#脊椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84567, encryptionId=dd238456e9f, topicName=脊椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80c21536506, createdName=neizongke, createdTime=Thu Jul 12 06:09:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
    2012-07-12 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1891009, encodeId=f2c418910095f, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Mar 27 06:09:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328833, encodeId=cdce13288336d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Jul 12 06:09:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630481, encodeId=366f163048157, content=<a href='/topic/show?id=dd238456e9f' target=_blank style='color:#2F92EE;'>#脊椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84567, encryptionId=dd238456e9f, topicName=脊椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80c21536506, createdName=neizongke, createdTime=Thu Jul 12 06:09:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
    2012-07-12 neizongke